Close

Plus Therapeutics (PSTV) Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT Glioblastoma Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. BA
7. HCP
8. SNAP
9. TMUS
10. MSFT


Go back to Plus Therapeutics (PSTV) Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT Glioblastoma Trial

Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial

June 16, 2021 7:30 AM EDT

AUSTIN, Texas, June 16, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the Company), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that the Data and Safety... More